AMGN AMGEN Earnings and EPS analysis

Relative Growth: Rel. Growth:

Relative Strength: Rel. Strength:

Relative Valuation: Rel. Valuation:

Relative Profitability: Rel. Profitability: 95

EPS in 2026 (TTM): $17.38

Last Report Period Date: Sep 30, 2026

As of November 2026, AMGN's current EPS stands at $17.38, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of $14.33, which marks an increase compared to its EPS of $7.62 in 2024. AMGN reported an EPS of $7.14 for the quarterly report ending on Sep 30, 2026.

AMGN earnings history

Historical annual and quarterly earnings per share (EPS) data for AMGEN

EPS (TTM)

$17.38

EPS Growth YoY (Quarterly)

19.4%

EPS (Quarterly)

$7.14

EPS Growth (Quarterly)

62.3%

For 2025, AMGEN's EPS was $14.33, an increase of 88.1% from $7.62 in 2024. For the fiscal quarter that ended on Sep 30, 2026, the per-share earnings was $7.14, showing a 19.4% increase from the same quarter last year. For the twelve months ending September 2026, the EPS is $17.38. For the year 2024, the yearly earnings per share was $7.62, marking a decrease of 39.3% from 2023.

AMGN EPS vs price chart

AMGN EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

19.4%

EPS growth YoY

88.1%

EPS growth 3Y avg

5.6%

EPS growth 5Y avg

2.9%

AMGEN has registered an increase in EPS of 19.4% during the last 12 months (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of 5.6% per year for the last three years. AMGEN had an average annual EPS growth rate of 2.9% during the last 5 years. A 10-year view shows that AMGN has seen an average EPS growth of 4.6% per year.

AMGN Earnings Waterfall

Breakdown of revenue, profit and net income for AMGEN

AMGN Earnings vs Peers

What are the earnings of AMGN compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
BMY Bristol-Myers Squibb Company	13.76	178.7%	5.3%	N/A
AMGN AMGEN Inc	26.92	88.1%	5.6%	2.9%
ILMN Illumina Inc	35.54	171.1%	N/A	4.1%
ABT Abbott Laboratories	39.79	-51.4%	-1.8%	8.2%
PFE Pfizer Inc	40.7	-3.5%	-37.4%	-3.7%
JNJ Johnson & Johnson	42.62	90.6%	17.7%	14.8%
LLY Lilly(Eli) & Company	46.57	95.6%	49.2%	27.5%
ABBV Abbvie Inc	50.71	-1.3%	-29.1%	-2.8%
BIIB Biogen Inc	106.94	-21.2%	-25%	-18.7%
GILD Gilead Sciences Inc	N/A	1,700%	23.2%	132.8%

All data is based on quarterly TTM periods, unless otherwise specified.